Research Topics
Species | Virginia G KaklamaniSummaryAffiliation: Northwestern University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Role of capecitabine (Xeloda) in breast cancerVirginia G Kaklamani
Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Expert Rev Anticancer Ther 3:137-44. 2003..This review will place the available data on the use of capecitabine in metastatic breast cancer as a single agent or as part of a combination regime in context...- TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studiesVirginia G Kaklamani
Cancer Genetics Program, Division of Hematology Oncology, Evanston Northwestern Healthcare, Chicago, IL, USA
J Clin Oncol 21:3236-43. 2003..This study was undertaken to analyze all published case-control studies on TGFBR1*6A and cancer and determine whether TGFBR1*6A is associated with cancer... - Gene expression in breast cancerVirginia G Kaklamani
Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine of Northwestern University, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA
Curr Treat Options Oncol 7:123-8. 2006..Tailoring our treatment based on individual tumor characteristics will help us develop better therapeutic strategies and save many patients from receiving unnecessary toxic therapy... 
Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer riskVirginia G Kaklamani
Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Cancer Res 68:3178-84. 2008..89; P(trend) = 0.001). This is the first report of an association between functionally relevant variants of the adiponectin pathway and breast cancer risk. The results warrant further studies of the adiponectin pathway in breast cancer...- Targeting angiogenesis in metastatic breast cancerSangeetha Reddy
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
Oncologist 17:1014-26. 2012..Sequential use of antiangiogenic agents with differing mechanisms of action may be an effective approach. Despite setbacks, angiogenesis will likely remain an important target of treatment for selected patients with MBC... 
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinibVirginia G Kaklamani
Division of Hematology Oncology, Northwestern University, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
Breast Cancer Res Treat 132:833-42. 2012..This combination offers an alternative non-anthracycline-containing regimen for women with HER2 positive breast cancer...- The role of the fat mass and obesity associated gene (FTO) in breast cancer riskVirginia Kaklamani
Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine and Robert H, Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 676 N St Clair st suite 850, Chicago, IL 60611, USA
BMC Med Genet 12:52. 2011..Our objective was to evaluate tissue expression of FTO in breast and the role of FTO SNPs in predicting breast cancer risk... - Role of TGF-beta in cancer and the potential for therapy and preventionVirginia G Kaklamani
Northwestern University Feinberg School of Medicine, Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 880, Chicago, IL 60611, USA
Expert Rev Anticancer Ther 4:649-61. 2004..In addition, it is predicted that inhibitors of the TGF-beta signaling pathway will find their way into cancer clinical trials, leading to delays in tumor progression and improvements in overall survival... - Global experience with ixabepilone in breast cancerVirginia G Kaklamani
Cancer Genetics Program, Division of Hematology Oncology, Northwestern University, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
Expert Rev Anticancer Ther 11:683-92. 2011..Further information on the global patterns of use of ixabepilone will assist in optimizing the use of this novel therapy... - A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DXVirginia Kaklamani
Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine of Northwestern University 676 North St Clair Street, Suite 850, Chicago, IL, USA
Expert Rev Mol Diagn 6:803-9. 2006..Tailoring our treatment based on individual tumor characteristics will help us develop better therapeutic strategies and save many of our patients from receiving unnecessary toxic therapy... - Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer riskVirginia G Kaklamani
Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair Street, Chicago, IL 60611, USA
Cancer Res 65:3454-61. 2005..25-3.87). This is the first study assessing the TGF-beta signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population... - Role of polymorphisms in Adamantiades-Behçet's diseaseVirginia G Kaklamani
Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, and Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
J Rheumatol 35:2376-8. 2008..We tested whether incidence of these polymorphisms would differ in patients with A-BD compared with healthy controls of similar age and geographic location... - Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer riskVirginia G Kaklamani
Cancer Genetics Program, Division of Hematology and Oncology, Department of Medicine and Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
JAMA 300:1523-31. 2008..While there is evidence of an association between circulating adiponectin levels and colorectal cancer risk, no association between genes of the adiponectin pathway and colorectal cancer have been reported to date... - Adjuvant therapy of breast cancerVirginia G Kaklamani
Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine of Northwestern University, Chicago, Illinois 60611, USA
Cancer Invest 23:548-60. 2005.... - TGFBR1*6A may contribute to hereditary colorectal cancerYansong Bian
Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Suite 880, Chicago, IL 60611, USA
J Clin Oncol 23:3074-8. 2005..To test this hypothesis, we determined whether TGFBR16A contributes to a proportion of mismatch repair (MMR) gene mutation-negative hereditary nonpolyposis colorectal cancer (HNPCC) patients... - The assessment and management of cancer treatment-related diarrheaVirginia G Kaklamani
Northwestern Medical Faculty Foundation, Northwestern University, Chicago, IL 60611, USA
Clin Colorectal Cancer 4:375-81; discussion 382-3. 2005..Early recognition and management of diarrhea will be essential to improve control of diarrhea, and in turn will positively impact patients' quality of life... - HER2-positive breast cancer: current and future treatment strategiesRyan H Engel
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Drugs 67:1329-41. 2007..Whereas pertuzumab, a humanised monoclonal antibody, directed against heterodimerisation of HER2 and HER3 has entered phase II and III clinical trials... - Somatic acquisition and signaling of TGFBR1*6A in cancerBoris Pasche
Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, The Feinberg School of Medicine, Northwestern, University, Chicago, Ill 60611, USA
JAMA 294:1634-46. 2005..Epidemiological studies suggest that TGFBR1*6A may act as a tumor susceptibility allele. How TGFBR1*6A contributes to cancer development is largely unknown... - No major association between TGFBR1*6A and prostate cancerVirginia Kaklamani
Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
BMC Genet 5:28. 2004..080) but the differences in TGFBR1*6A genotype distribution between cases and controls did not reach statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the development of prostate cancer... - Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPsBoris Pasche
Division of Hematology Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35203, USA
J Exp Clin Cancer Res 29:57. 2010..This phenotype was first observed in mice, then in lymphoblastoid cell lines from patients with microsatellite stable colorectal tumors... - Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer developmentYansong Bian
Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine, Northwestern University, Chicago, IL 60611, USA
Hum Mol Genet 16:3128-35. 2007..They also represent the first human report of somatically acquired altered stromal TGF-beta signaling during oncogenesis and the first report of a concordant mutation in the stromal and epithelial compartments in colon cancer... - Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?Virginia G Kaklamani
Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Clin Breast Cancer 4:S26-33. 2003..In this article, we are attempting to provide an overview of current use of doxorubicin and epirubicin in breast cancer.. - New insights into breast cancer genetics and impact on patient managementDiana S Rosman
Cancer Genetics Program, Division of Hematology Oncology, Department of Medicine and Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Curr Treat Options Oncol 8:61-73. 2007..In the next decade, screening for combinations of high and low penetrance genes will likely permit the identification of a large fraction of inherited breast cancer cases and will further reduce the burden of familial breast cancer... - Role of efaproxiral in metastatic brain tumorsRyan H Engel
Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, 676 North Street Clair Street, Suite 850, Chicago, IL 60622, USA
Expert Rev Anticancer Ther 6:477-85. 2006..Furthermore, the combination of efaproxiral with radiotherapy is being investigated in other solid tumors... - Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathologyDaniel E Abbott
Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Cancer Biol Ther 9:23-30. 2010.... - Transforming Growth Factor Beta and breast cancerVirginia Kaklamani
Division of Hematology/Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Cancer Treat Res 126:129-56. 2005 - 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survivalAffaan K Bangash
Department of Radiology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 800, Chicago, IL 60611, USA
J Vasc Interv Radiol 18:621-8. 2007..To present data from patients with breast cancer liver metastases who underwent radioembolization with yttrium (90Y) microspheres... - New targeted therapies in breast cancerVirginia Kaklamani
Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Semin Oncol 31:20-5. 2004..In the next few years, and as trials with the above agents mature, we will further define the role of these targeted agents in the treatment of breast cancer... - TGF-beta signaling alterations in cancerYansong Bian
Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
Cancer Treat Res 115:73-94. 2003 - Adjuvant therapy of breast cancer in the elderly: does one size fit all?William J Gradishar
JAMA 293:1118-20. 2005